149 related articles for article (PubMed ID: 33015747)
21. Doxorubicin-resistant osteosarcoma: novel therapeutic approaches in sight?
Hattinger CM; Fanelli M; Tavanti E; Vella S; Riganti C; Picci P; Serra M
Future Oncol; 2017 Apr; 13(8):673-677. PubMed ID: 28183198
[No Abstract] [Full Text] [Related]
22. TFAP2C-mediated LINC00922 signaling underpins doxorubicin-resistant osteosarcoma.
Gu Z; Zhou Y; Cao C; Wang X; Wu L; Ye Z
Biomed Pharmacother; 2020 Sep; 129():110363. PubMed ID: 32563982
[TBL] [Abstract][Full Text] [Related]
23. Premedication with pioglitazone prevents doxorubicin-induced left ventricular dysfunction in mice.
Furihata T; Maekawa S; Takada S; Kakutani N; Nambu H; Shirakawa R; Yokota T; Kinugawa S
BMC Pharmacol Toxicol; 2021 May; 22(1):27. PubMed ID: 33962676
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-221 Upregulates the Expression of P-gp and Bcl-2 by Activating the Stat3 Pathway to Promote Doxorubicin Resistance in Osteosarcoma Cells.
Liu Y; Liu X; Yang S
Biol Pharm Bull; 2021 Jun; 44(6):861-868. PubMed ID: 33828027
[TBL] [Abstract][Full Text] [Related]
25. Targeting ABCB1 (MDR1) in multi-drug resistant osteosarcoma cells using the CRISPR-Cas9 system to reverse drug resistance.
Liu T; Li Z; Zhang Q; De Amorim Bernstein K; Lozano-Calderon S; Choy E; Hornicek FJ; Duan Z
Oncotarget; 2016 Dec; 7(50):83502-83513. PubMed ID: 27835872
[TBL] [Abstract][Full Text] [Related]
26. Icariin enhances cytotoxicity of doxorubicin in human multidrug-resistant osteosarcoma cells by inhibition of ABCB1 and down-regulation of the PI3K/Akt pathway.
Wang Z; Yang L; Xia Y; Guo C; Kong L
Biol Pharm Bull; 2015; 38(2):277-84. PubMed ID: 25747987
[TBL] [Abstract][Full Text] [Related]
27. Long noncoding RNA OIP5-AS1 mediates resistance to doxorubicin by regulating miR-137-3p/PTN axis in osteosarcoma.
Sun X; Tian C; Zhang H; Han K; Zhou M; Gan Z; Zhu H; Min D
Biomed Pharmacother; 2020 Aug; 128():110201. PubMed ID: 32460190
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of a nitrogen-containing bisphosphonate, minodronate, in conjunction with a p38 mitogen activated protein kinase inhibitor or doxorubicin against malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Sakai A; Ochi M
Cancer Chemother Pharmacol; 2008 Jun; 62(1):111-6. PubMed ID: 17874104
[TBL] [Abstract][Full Text] [Related]
29. Estrogen-functionalized liposomes grafted with glutathione-responsive sheddable chotooligosaccharides for the therapy of osteosarcoma.
Yin X; Feng S; Chi Y; Liu J; Sun K; Guo C; Wu Z
Drug Deliv; 2018 Nov; 25(1):900-908. PubMed ID: 29644882
[TBL] [Abstract][Full Text] [Related]
30. SIAH1/ZEB1/IL-6 axis is involved in doxorubicin (Dox) resistance of osteosarcoma cells.
Han X; Liu F; Zhang C; Ren Z; Li L; Wang G
Biol Chem; 2019 Mar; 400(4):545-553. PubMed ID: 30265649
[TBL] [Abstract][Full Text] [Related]
31. CD44 Contributes to the Regulation of MDR1 Protein and Doxorubicin Chemoresistance in Osteosarcoma.
Gerardo-Ramírez M; Keggenhoff FL; Giam V; Becker D; Groth M; Hartmann N; Straub BK; Morrison H; Galle PR; Marquardt JU; Herrlich P; Hartmann M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955749
[TBL] [Abstract][Full Text] [Related]
32. The combination of oral-recombinant methioninase and azacitidine arrests a chemotherapy-resistant osteosarcoma patient-derived orthotopic xenograft mouse model.
Higuchi T; Sugisawa N; Yamamoto J; Oshiro H; Han Q; Yamamoto N; Hayashi K; Kimura H; Miwa S; Igarashi K; Tan Y; Kuchipudi S; Bouvet M; Singh SR; Tsuchiya H; Hoffman RM
Cancer Chemother Pharmacol; 2020 Feb; 85(2):285-291. PubMed ID: 31705268
[TBL] [Abstract][Full Text] [Related]
33. Surfactin-based nanoparticles loaded with doxorubicin to overcome multidrug resistance in cancers.
Huang W; Lang Y; Hakeem A; Lei Y; Gan L; Yang X
Int J Nanomedicine; 2018; 13():1723-1736. PubMed ID: 29606866
[TBL] [Abstract][Full Text] [Related]
34. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.
Tu B; Zhu J; Liu S; Wang L; Fan Q; Hao Y; Fan C; Tang TT
Oncotarget; 2016 Jul; 7(30):48296-48308. PubMed ID: 27340780
[TBL] [Abstract][Full Text] [Related]
35. Prevention of MDR development in leukemia cells by micelle-forming polymeric surfactant.
Sharma AK; Zhang L; Li S; Kelly DL; Alakhov VY; Batrakova EV; Kabanov AV
J Control Release; 2008 Nov; 131(3):220-7. PubMed ID: 18722489
[TBL] [Abstract][Full Text] [Related]
36. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
37. Multidrug resistance mediated by overexpression of P-glycoprotein in human osteosarcoma in vivo.
Suto R; Abe Y; Nakamura M; Ohnishi Y; Yoshimura M; Lee YH; Imanishi T; Yamazaki H; Kijima H; Tokunaga T; Oshika Y; Hiraoka N; Tamaoki N; Fukuda H; Ueyama Y
Int J Oncol; 1998 Feb; 12(2):287-91. PubMed ID: 9458350
[TBL] [Abstract][Full Text] [Related]
38. The histone deacetylase inhibitor valproic acid sensitizes human and canine osteosarcoma to doxorubicin.
Wittenburg LA; Bisson L; Rose BJ; Korch C; Thamm DH
Cancer Chemother Pharmacol; 2011 Jan; 67(1):83-92. PubMed ID: 20306194
[TBL] [Abstract][Full Text] [Related]
39. Targeted inhibition of T-cell factor activity promotes syndecan-2 expression and sensitization to doxorubicin in osteosarcoma cells and bone tumors in mice.
Dieudonné FX; Marion A; Marie PJ; Modrowski D
J Bone Miner Res; 2012 Oct; 27(10):2118-29. PubMed ID: 22550000
[TBL] [Abstract][Full Text] [Related]
40. Application of tumor-targeting peptide-decorated polypeptide nanoparticles with doxorubicin to treat osteosarcoma.
Qiu R; Sun D; Bai Y; Li J; Wang L
Drug Deliv; 2020 Nov; 27(1):1704-1717. PubMed ID: 33305647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]